An efficient combination immunotherapy for antitumor immunity without accelerating cardiac allograft rejection.

Miao, Xiaolong; Wu, Zelai; Jiang, Yuancong; Liu, Han; Gong, Weihua

Miao, Xiaolong; Wu, Zelai; Jiang, Yuancong; Liu, Han; Gong, Weihua.

Affiliation

Miao X; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Wu Z; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Jiang Y; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Liu H; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Gong W; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.

Immunology ; 169(2): 157-166, 2023 06.

Article de En | MEDLINE | ID: mdl-36517459

Sujet(s)
Mots clés

BET protein inhibition; PD-L1; allograft rejection; immunotherapy; primary liver cancer

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du foie / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Immunology Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google